Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New Dual-Targeting CAR T-Cell therapy offers hope for relapsed childhood leukemia

NCT ID NCT05442515

First seen Feb 19, 2026 · Last updated May 22, 2026 · Updated 14 times

Summary

This study tests a new treatment for children and young adults (ages 3-39) with B-cell cancers like leukemia or lymphoma that have come back after standard therapy. The treatment uses a patient's own immune cells, which are modified in a lab to target two cancer proteins (CD19 and CD22) at once. After a short course of chemotherapy, the modified cells are given back to the patient. The goal is to see if this therapy is safe and effective in controlling the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • National Institutes of Health Clinical Center

    RECRUITING

    Bethesda, Maryland, 20892, United States

    Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.